Progyny Appoints Janet Choi, M.D., as Chief Medical Officer

3 years ago

Dr. Choi brings her more than 20 years of reproductive health experience to enhance the company’s current offerings and counsel…

Inovalon Expands Patient Data Connectivity Network by 110% Over 12 Months – Now Enabling Access to More Than 67% of U.S. Healthcare Providers

3 years ago

Expanded Access Further Eases Patient Data Exchange and Advances Industry InteroperabilityBOWIE, Md., April 04, 2023 (GLOBE NEWSWIRE) -- Inovalon, a…

Shineco Subsidiary’s ‘Cardiac 5-Minute Test’ Passes Quality Inspection by China Regulator NMPA

3 years ago

Approval Provides Strong Support for the Product’s Marketing in China BEIJING, April 04, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco”…

Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

3 years ago

FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic…

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

3 years ago

Tel Aviv, Israel / Vancouver, Canada, April 04, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:…

AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

3 years ago

Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditionsOCALA, Fla., April…

Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note

3 years ago

MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a…

Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board

3 years ago

EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence…

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

3 years ago

Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated…